mci 9038 has been researched along with Bone Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akita, N; Asanuma, K; Asanuma, Y; Hayashi, T; Matsumine, A; Okamoto, T; Sudo, A; Uchida, A; Wakabayashi, H; Yoshikawa, T | 1 |
| Asanuma, K; Hayashi, T; Kusuzaki, K; Matsumine, A; Okuyama, N; Seto, M; Suzuki, K; Uchida, A; Wakabayashi, H | 1 |
2 other study(ies) available for mci 9038 and Bone Cancer
| Article | Year |
|---|---|
The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone.
Topics: Animals; Antithrombins; Arginine; Body Weight; Bone Neoplasms; Breast Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Humans; Mice; Pipecolic Acids; Sulfonamides; Thrombin; Thromboplastin; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis.
Topics: Animals; Antineoplastic Agents; Antithrombins; Arginine; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Melanoma, Experimental; Mice; Pipecolic Acids; Sulfonamides | 2004 |